ProCE Banner Activity

ATLAS: Patient-Reported Outcomes From Phase III Study of Switch to Long-Acting Injectable Cabotegravir + Rilpivirine in Virologically Suppressed Patients

Slideset Download
Conference Coverage
97% of patients receiving long-acting injectable therapy said that they preferred it to continued daily oral ART.

Released: July 25, 2019

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Educational grant provided by:

Gilead

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2019

ProCE Banner